{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T11:28:32Z","timestamp":1753356512267},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.juro.2010.02.004","type":"journal-article","created":{"date-parts":[[2010,4,19]],"date-time":"2010-04-19T08:48:58Z","timestamp":1271666938000},"page":"2395-2402","source":"Crossref","is-referenced-by-count":8,"title":["Identification of Tumor and Invasion Suppressor Gene Modulators in Bladder Cancer by Different Classes of Histone Deacetylase Inhibitors Using Reverse Phase Protein Arrays"],"prefix":"10.1097","volume":"183","author":[{"given":"Justin J.","family":"Gould","sequence":"first","affiliation":[{"name":"Department of Urology, Burlington, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick A.","family":"Kenney","sequence":"additional","affiliation":[{"name":"Department of Urology, Burlington, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly M.","family":"Rieger-Christ","sequence":"additional","affiliation":[{"name":"Lahey Clinic, Burlington, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brasil Silva","family":"Neto","sequence":"additional","affiliation":[{"name":"Lahey Clinic, Burlington, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew F.","family":"Wszolek","sequence":"additional","affiliation":[{"name":"Department of Urology, Burlington, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"LaVoie","sequence":"additional","affiliation":[{"name":"Cell and Molecular Biology Laboratory, Burlington, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia H.","family":"Holway","sequence":"additional","affiliation":[{"name":"Aushon Biosystems, Inc., Billerica, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"Spurrier","sequence":"additional","affiliation":[{"name":"Aushon Biosystems, Inc., Billerica, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Austin","sequence":"additional","affiliation":[{"name":"Aushon Biosystems, Inc., Billerica, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard K.","family":"Cammarata","sequence":"additional","affiliation":[{"name":"Cell and Molecular Biology Laboratory, Burlington, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Canes","sequence":"additional","affiliation":[{"name":"Department of Urology, Burlington, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Libertino","sequence":"additional","affiliation":[{"name":"Department of Urology, Burlington, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian C.","family":"Summerhayes","sequence":"additional","affiliation":[{"name":"Lahey Clinic, Burlington, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2010.02.004_bib1","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s10147-008-0811-1","article-title":"Epigenetics in bladder cancer","volume":"13","author":"Enokida","year":"2008","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.juro.2010.02.004_bib2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/450357a","article-title":"Epigenetics: reversing the \u2018irreversible\u2019","volume":"450","author":"Jones","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.juro.2010.02.004_bib3","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"Xu","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.juro.2010.02.004_bib4","first-page":"7089","article-title":"Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer","volume":"63","author":"Belinsky","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.juro.2010.02.004_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/nrc1779","article-title":"Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer","volume":"6","author":"Minucci","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.juro.2010.02.004_bib6","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.1073\/pnas.180316197","article-title":"Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation","volume":"97","author":"Richon","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.juro.2010.02.004_bib7","first-page":"151","article-title":"Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines","volume":"2","author":"Glaser","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.juro.2010.02.004_bib8","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/ijc.20634","article-title":"Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo","volume":"113","author":"Canes","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.juro.2010.02.004_bib9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1442-2042.2006.01344.x","article-title":"Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest","volume":"13","author":"Li","year":"2006","journal-title":"Int J Urol"},{"key":"10.1016\/j.juro.2010.02.004_bib10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1124\/jpet.106.106658","article-title":"Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells","volume":"319","author":"Chen","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.juro.2010.02.004_bib11","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1158\/1535-7163.MCT-06-0586","article-title":"Proapoptotic ability of oncogenic H-Ras to facilitate apoptosis induced by histone deacetylase inhibitors in human cancer cells","volume":"6","author":"Choudhary","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.juro.2010.02.004_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1479-5876-5-49","article-title":"The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo","volume":"5","author":"Buckley","year":"2007","journal-title":"J Transl Med"},{"key":"10.1016\/j.juro.2010.02.004_bib13","article-title":"Experimental study on inhibitory effects of histone deacetylase inhibitor MS-275 and TSA on bladder cancer cells","author":"Qu","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.juro.2010.02.004_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: what are the cancer relevant targets?","volume":"277","author":"Witt","year":"2009","journal-title":"Cancer Lett"},{"key":"10.1016\/j.juro.2010.02.004_bib15","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10585-007-9131-5","article-title":"Histone deacetylases: target enzymes for cancer therapy","volume":"25","author":"Mottet","year":"2008","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.juro.2010.02.004_bib16","first-page":"971","article-title":"Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo","volume":"7","author":"Vigushin","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2010.02.004_bib17","first-page":"2292","article-title":"A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies","volume":"7","author":"Gilbert","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2010.02.004_bib18","first-page":"3047","article-title":"A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule","volume":"7","author":"Carducci","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2010.02.004_bib19","first-page":"718","article-title":"Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms","volume":"8","author":"Sandor","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2010.02.004_bib20","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.juro.2010.02.004_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/sj.bjc.6603851","article-title":"Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial","volume":"97","author":"Atmaca","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2010.02.004_bib22","first-page":"4154","article-title":"Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors","volume":"56","author":"Shimazui","year":"1996","journal-title":"Cancer Res"},{"key":"10.1016\/j.juro.2010.02.004_bib23","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1038\/sj.onc.1207629","article-title":"Novel expression of N-cadherin elicits in vitro bladder cell invasion via the Akt signaling pathway","volume":"23","author":"Rieger-Christ","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.juro.2010.02.004_bib24","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1111\/j.1464-410X.2008.08115.x","article-title":"P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cells","volume":"102","author":"Mandeville","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2010.02.004_bib25","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1158\/1078-0432.CCR-06-2330","article-title":"Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors","volume":"13","author":"Baumgart","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2010.02.004_bib26","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.juro.2007.05.113","article-title":"Epidermal growth factor receptor status and the response of bladder carcinoma cells to erlotinib","volume":"178","author":"Jacobs","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2010.02.004_bib27","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1038\/sj.bjc.6602651","article-title":"Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential","volume":"92","author":"Rieger-Christ","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.juro.2010.02.004_bib28","first-page":"3228","article-title":"Gelsolin: a candidate for suppressor of human bladder cancer","volume":"55","author":"Tanaka","year":"1995","journal-title":"Cancer Res"},{"key":"10.1016\/j.juro.2010.02.004_bib29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/1097-0142(19810101)47:1<104::AID-CNCR2820470118>3.0.CO;2-8","article-title":"Correlation between numbers of desmosomes and the aggressiveness of transitional cell carcinoma in human urinary bladder","volume":"47","author":"Alroy","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2010.02.004_bib30","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1158\/1535-7163.MCT-08-0810","article-title":"Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays","volume":"7","author":"Boyd","year":"2008","journal-title":"Mol Cancer Ther"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534710002454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534710002454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2010.02.004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T01:47:38Z","timestamp":1651196858000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2010.02.004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["10.1016\/j.juro.2010.02.004"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2010.02.004","relation":{},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}